DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07088718

DUP-SURPASS

Completed

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

Assets

Dulaglutide / Tirzepatide

Listed sites

1

Recruiting sites

—

Enrollment

44,671

actual

Study population

Cardiovascular disease, Type 2 diabetes

Key I/E criterion

•BMI ≥25

Primary endpoint

•Expanded / custom MACE composite (All-cause death, Myocardial infarction (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07088718
Org study ID2018P002966-DUP-SURPASSCVOT

Timeline

Milestones

Study start2024-10-01actual
Study first posted2025-07-28actual
Primary completion2025-07-30actual
Study completion2025-07-30actual
Last update posted2025-10-15actual

Assets

Investigational agents

DulaglutideTirzepatide

Study populations

Who this study enrolls

Cardiovascular diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age40 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Individuals aged 40 years or older with T2DM and an established CVD

Inclusion criteria

FOLLOWING ELIGIBILITY CIRTERIA OF THE SURPASS-CVOT TRIAL

Inclusion Criteria:

•History of MI, surgical or percutaneous coronary/carotid peripheral artery revascularization
•BMI ≥25.0kg/m2
•Type 2 diabetes, diagnosis of coronary/carotid/peripheral artery disease
•Age ≥40 years
•Male or female sex

Exclusion criteria

•Medullary thyroid carcinoma, MEN syndrome type 2, malignancy
•Treatment for diabetic retinopathy//macular edema, pancreatitis, gastric emptying abnormality/bariatric surgery, liver disease, end-stage renal disease or dialysis, pregnancy
•Prior use of pramlintide or any GLP-1-RA except tirzepatide or dulaglutide
•Cardiovascular event, hospitalization for heart failure
•Concurrent use of both drugs i.e. tirzepatide and dulaglutide

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes
2
Other clinical outcomes
2

Cardiovascular outcomes

2 endpoints
Primary/protocol endpoint

First occurence of MACE (all-cause mortailty, myocardial infarction, or death)

Time frame:1 day after cohort entry date until the first of outcome or censoring, up to 365 days

Expanded / custom MACE composite

time to event, event

componentsAll-cause death, Myocardial infarction (any)

Secondary/protocol endpoint

Individual components of the primary endpoint, i.e., all-cause mortality, myocardial infarction, or stroke (Tirzepatide vs dulaglutide)

Time frame:1 day after cohort entry date until the first of outcome or censoring, up to 365 days

time to event, event

Other clinical outcomes

2 endpoints
Secondary/protocol endpoint

Hernia

Time frame:1 day after cohort entry date until the first of outcome or censoring, up to 365 days

time to event, event

Secondary/protocol endpoint

Lumbar radiculopathy

Time frame:1 day after cohort entry date until the first of outcome or censoring, up to 365 days

time to event, event

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.